Mar 21, 2017 04:19 PM IST | Source: CNBC-TV18

Expect 15-20% cut in Divis Labs' FY18-FY19 EPS estimates: HDFC Sec

In an interview to CNBC-TV18, Amey Chalke, Pharma Analyst at HDFC Securities shared his readings and outlook on Divis Laboratories and Dr Reddys Laboratories.

In an interview to CNBC-TV18, Amey Chalke, Pharma Analyst at HDFC Securities shared his readings and outlook on Divis Laboratories and Dr Reddys Laboratories.

Chalke assumes 15-20 percent cut in FY18 and FY19 earnings per share (EPS) estimates on Divis Labs.

Speaking about Dr Reddys, he says some of the observations on Dr Reddy's Duvvada unit look critical in nature and company may take some time to resolve issues with regards to Duvvada observations, he adds.

Sections
Follow us on
Available On